He Y - Search Results

1

Distinct mechanisms of neutralization by monoclonal antibodies specific for sites in the N-terminal or C-terminal domain of murine leukemia virus SU.

Burkhart MD, Kayman SC, He Y, Pinter A. Burkhart MD, et al. Among authors: he y. J Virol. 2003 Apr;77(7):3993-4003. doi: 10.1128/jvi.77.7.3993-4003.2003. J Virol. 2003. PMID: 12634359 Free PMC article.

2

Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci.

He Y, Honnen WJ, Krachmarov CP, Burkhart M, Kayman SC, Corvalan J, Pinter A. He Y, et al. J Immunol. 2002 Jul 1;169(1):595-605. doi: 10.4049/jimmunol.169.1.595. J Immunol. 2002. PMID: 12077293

3

Analysis of the immunogenic properties of a single-chain polypeptide analogue of the HIV-1 gp120-CD4 complex in transgenic mice that produce human immunoglobulins.

He Y, D'Agostino P, Pinter A. He Y, et al. Vaccine. 2003 Oct 1;21(27-30):4421-9. doi: 10.1016/s0264-410x(03)00451-1. Vaccine. 2003. PMID: 14505925

4

The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.

Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, Kayman SC. Pinter A, et al. Among authors: he y. J Virol. 2004 May;78(10):5205-15. doi: 10.1128/jvi.78.10.5205-5215.2004. J Virol. 2004. PMID: 15113902 Free PMC article.

5

Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.

He Y, Zhu Q, Liu S, Zhou Y, Yang B, Li J, Jiang S. He Y, et al. Virology. 2005 Mar 30;334(1):74-82. doi: 10.1016/j.virol.2005.01.034. Virology. 2005. PMID: 15749124 Free PMC article.

6

Characterization of antibodies that inhibit HIV gp120 antigen processing and presentation.

Tuen M, Visciano ML, Chien PC Jr, Cohen S, Chen PD, Robinson J, He Y, Pinter A, Gorny MK, Hioe CE. Tuen M, et al. Among authors: he y. Eur J Immunol. 2005 Sep;35(9):2541-51. doi: 10.1002/eji.200425859. Eur J Immunol. 2005. PMID: 16106369 Free article.

7

Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.

He Y, Li J, Heck S, Lustigman S, Jiang S. He Y, et al. J Virol. 2006 Jun;80(12):5757-67. doi: 10.1128/JVI.00083-06. J Virol. 2006. PMID: 16731915 Free PMC article.

8

Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines.

Du L, He Y, Wang Y, Zhang H, Ma S, Wong CK, Wu SH, Ng F, Huang JD, Yuen KY, Jiang S, Zhou Y, Zheng BJ. Du L, et al. Among authors: he y. Virology. 2006 Sep 15;353(1):6-16. doi: 10.1016/j.virol.2006.03.049. Epub 2006 Jun 21. Virology. 2006. PMID: 16793110 Free PMC article.

9

Conserved salt bridge between the N- and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition.

He Y, Liu S, Li J, Lu H, Qi Z, Liu Z, Debnath AK, Jiang S. He Y, et al. J Virol. 2008 Nov;82(22):11129-39. doi: 10.1128/JVI.01060-08. Epub 2008 Sep 3. J Virol. 2008. PMID: 18768964 Free PMC article.

10

Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients.

Cao Z, Liu L, Du L, Zhang C, Jiang S, Li T, He Y. Cao Z, et al. Among authors: he y. Virol J. 2010 Nov 4;7:299. doi: 10.1186/1743-422X-7-299. Virol J. 2010. PMID: 21047436 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

40,781 results

Search Page

Filters